- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04349930
The CBD-IC Randomized Controlled Trial: Evaluation of Hemp Cannabidiol SuppositoRies for Pain and Urinary SymptOms in INterstitial Cystitis (CHRONIC) (CHRONIC)
January 12, 2021 updated by: Gena Dunivan, University of New Mexico
This study seeks to exploit bladder cannabidiol receptors as a therapeutic drug target by conducting a double-masked, placebo-controlled randomized trial evaluating the effects of vaginal hemp cannabidiol (CBD) suppositories on lower urinary tract symptoms (LUTS), pain severity, and sexual function.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is a chronic inflammatory disease with an insidious course and is detrimental weight to women's quality of life, sexual function, and general health.
IC/BPS affects nearly 1.2 million women in the United States and although there are currently six lines of treatment, they lack high level evidence and sufficient efficacy.
New therapies are in high demand.
As the cannabis industry gains popularity in medicine, research has revealed prevalent expression of cannabinoid receptors in bladder detrusor muscle and urothelium suggesting a novel drug target for IC/BPS.
This study seeks to exploit this target by conducting a double-masked, placebo-controlled randomized trial evaluating the effects of vaginal hemp cannabidiol (CBD) suppositories on lower urinary tract symptoms (LUTS), pain severity, and sexual function.
Women with diagnosed IC/BPS will be randomized to treatment with a placebo vaginal suppository or a hemp CBD vaginal suppository.
We will monitor changes in their LUTS, pain, and sexual function using validated questionnaires.
Our goal is to evaluate whether CBD is an effective, low-risk and less invasive treatment option for IC/BPS.
Attainment of this goal would demonstrate a potential novel use for CBD in our Urogynecology patient population.
Study Type
Interventional
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131
- University of New Mexico
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Female Subjects ≥ 18 years of age
- Interstitial cystitis (IC) diagnosis
- English speaking/reading
- Prior treatment with one known treatment for IC: behavioral modifications, pelvic floor physical therapy, medications (amitriptyline, cimetidine, pentosane polysulfate sodium, or hydroxyzine), bladder instillations, bladder hydrodistention, cystoscopic fulguration or injection of Hunner's lesions, intradetrusor injection of botulinum toxin, or sacral neuromodulation
- Females of childbearing potential must use contraception throughout the study period (hormonal contraception, diaphragm, cervical cap, vaginal sponge, condoms, vasectomy, long acting reversible contraception)
- Females of non-child bearing potential must be post-menopausal defined as: > 51yo with no menses within the past 12mo or history of hysterectomy or history of bilateral oophorectomy or bilateral tubal ligation
Exclusion Criteria:
- THC or cannabidiol use within 1 month prior to enrollment per patient report
- Positive urine marijuana drug test on day of study enrollment
- Plan to use concomitant THC or cannabidiol of any form during the 6 week study period
- Inability to speak/understand English
- Pregnant or planning on becoming pregnant
- Unable to be contacted for follow up by telephone
- Cocoa butter allergy
- AST or ALT greater than 3 times the upper limit of normal at time of enrollment
- Females of childbearing potential with a positive urine pregnancy test at screening/prior to administration of Day 1 of treatment
- Subjects taking prescription or non-prescription medication which are substrates of CYP3A4, CYP2C19, CYP2C8, CYP2C9, CYP2C19, CYP1A2 and CYP2B6 within 14 days of the study procedure
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cannabidiol
CBD vaginal suppository
|
Cannabidiol vaginal suppository
|
Placebo Comparator: Placebo
Placebo vaginal suppository
|
Placebo vaginal suppository
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Urinary Pain Severity Scores
Time Frame: 6 weeks
|
Compare the efficacy of vaginal CBD suppositories versus vaginal placebo suppositories on pain severity symptoms in IC/BPS patients, as measured by composite pain severity sub-scores of the Genitourinary Pain Index (GUPI) & Interstitial Cystitis Symptom Index (ICSI).
The score ranges from 0-27 composite score with higher scores being consistent with more symptomatic disease.
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Urinary Symptom Severity Scores
Time Frame: 6 weeks
|
Compare the efficacy of vaginal CBD suppositories versus vaginal placebo suppositories on lower urinary tract symptoms as measured by the composite urinary severity sub-scores of the Genitourinary Pain Index (GUPI) & Interstitial Cystitis Symptom Index (ICSI).
The score ranges from 0-25 composite score with higher scores being consistent with more symptomatic disease.
|
6 weeks
|
Marijuana Urine Drug Test
Time Frame: 6 weeks
|
Evaluate the effect of routine use of vaginal CBD suppositories on a standard over-the-counter marijuana urine drug test
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Gena Dunivan, M.D., University of New Mexico Department of Urogynecology
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
January 1, 2021
Primary Completion (Anticipated)
July 1, 2022
Study Completion (Anticipated)
September 1, 2022
Study Registration Dates
First Submitted
April 13, 2020
First Submitted That Met QC Criteria
April 13, 2020
First Posted (Actual)
April 16, 2020
Study Record Updates
Last Update Posted (Actual)
January 15, 2021
Last Update Submitted That Met QC Criteria
January 12, 2021
Last Verified
January 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 00-000
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Interstitial Cystitis
-
Asan Medical CenterCompletedChronic Interstitial CystitisKorea, Republic of
-
St. Louis UniversityTerminated
-
St. Louis UniversityCompletedInterstitial Cystitis
-
Northwell HealthWithdrawnInterstitial CystitisUnited States
-
CAMC Health SystemCompletedInterstitial CystitisUnited States
-
UroGen Pharma Ltd.CompletedInterstitial Cystitis | ICIsrael
-
St. Louis UniversityCompleted
-
Drexel University College of MedicineMedtronicCompleted
-
AllerganTARIS Biomedical, Inc.TerminatedInterstitial CystitisUnited States, Canada
Clinical Trials on Cannabidiol vaginal suppository
-
Padagis LLCCompleted
-
Seed HealthActive, not recruitingVaginal Personal CareUnited States
-
Hatem AbuHashimUnknownVulvovaginal Candidiasis
-
University of Sao Paulo General HospitalCompletedProgesterone Resistance | Polycystic Ovary
-
Thomas Jefferson UniversityRecruiting
-
Laboratoires Techni PharmaCompleted
-
Laboratoires Techni PharmaCompleted
-
RDD Pharma LtdWithdrawn
-
Peking University Shenzhen HospitalRecruiting
-
Thomas Jefferson UniversityCompleted